Healthcare
Cyclopharm Limited (ASX:CYC)
Industry Group : Health Care Equipment & Services | Industry Group Name : Health Care Equipment & Supplies
Market Price : AUD 1.670.045 (2.769%)
(as on 2021-09-28 09:55:21)
| Previous Close | Open | Close* | Day Range | 52 WEEK HIGH LOW |
|---|---|---|---|---|
| 1.625 | 1.645 | 1.67 | 1.64L 1.72 H | 1.545L 3.45 H |
| Last Trade | 1.67 |
|---|---|
| Change% | 2.7692 |
| 52 W H/L | 3.45/1.545 |
| EBITDA | -3.056 M |
|---|---|
| NPAT After Abnormal Items | -6.044 M |
| Equity | 17.116 M |
| ROE% | -35.33% |
| Total Liabilities | 11.159 M |
|---|---|
| Total Revenue | 18.176 M |
| Cash and Cash Equivalents | 1.874 M |
Stock Information
| Share price | 1.67 |
|---|---|
| Market Cap | 155.936 M |
| Price/Gross Cash Flow | -66.01 |
| Dividend Yield Excluding Special | 0.40% |
| Ending Shares | 80.274 M | 52-Week Range | 1.545-3.45 |
| P/E ratio | 0.000 |
|---|---|
| Sector P/E | -- | EPS | -7.89 |
| EV/EBITDA | -- |
| Net Profit Margin (%) | -41.20% |
| Gross Cash Flows Per Share | -0.04 |
| Net Gearing | 16.55% |
| Gross DPS (AUD) | 0.01 |
|---|---|
| Gross Dividend Yield (Annualized) | 0.40% |
| Earnings Yield | 0.000 |
| Net Tangible Asset (NTA) | 0.15 |
| Sales Per Share | 0.19 |
| Book Value Per Share | 0.21 |
Announcements
About Company
Australian radiopharmaceutical company, Cyclopharm Limited (ASX: CYC) is focused on innovative solutions in nuclear medicine, targeted towards lung health. Serving the global medicine community since 1986, the company’s proprietary medical device and pharmaceutical products are made available under TechnegasTM, which is considered as the industry gold-standard in diagnostic functional lung imaging technology. Cyclopharm distributes its products in 57 countries with more than 1,500 nuclear medicine departments using TechnegasTM.
Corporate Information
|
|
|
|
Unit 4, 1 The Crescent, KINGSGROVE, NSW, AUSTRALIA, 2208
(02) 9541 0411
Dividends
| Ex-Dividend Date | Franking | DPS (AUD) | Dividend Yield |
|---|---|---|---|
| 30/12/2020 | 0% | 0.010 | 0.40% |
| 30/12/2019 | 0% | 0.010 | 0.85% |
| 30/12/2018 | 0% | 0.010 | 0.90% |
| 30/12/2017 | 0% | 0.010 | 1.05% |
| 30/12/2016 | 12% | 0.010 | 1.15% |
| 30/12/2015 | 100% | 0.010 | 2.75% |
| 30/12/2014 | -- | 0.000 | 0.00% |
| 30/12/2013 | -- | 0.000 | 0.00% |
| 30/12/2012 | -- | 0.000 | 0.00% |
| 30/12/2011 | -- | 0.000 | 0.00% |
Event Calendar
| Event Type | Event Date | Event Year |
|---|---|---|
| Report (Interim) | 2022-08-22 | 2022 |
| Report (Annual) | 2022-03-28 | 2022 |
| Report (Prelim) | 2022-02-24 | 2022 |
Financials
| Breakdown | 30/12/2020 | 30/12/2019 | 30/12/2018 | 30/12/2017 | 30/12/2016 |
|---|---|---|---|---|---|
| Trading Revenue | 14.523 M | 14.079 M | 13.404 M | 13.189 M | 14.386 M |
| Other Revenue | 3.652 M | 4.404 M | 2.122 M | 2.391 M | 0 |
| Total Revenue | 18.176 M | 18.482 M | 15.527 M | 15.579 M | 14.386 M |
| Interest Income | 4,410 | 25,513 | 103,411 | 79,529 | 47,308 |
| Interest Expenses | -207,859 | -280,259 | -26,129 | -20,079 | -17,952 |
| Expenses | -22.909 M | -19.904 M | -15.289 M | -14.616 M | -12.887 M |
| EBITDA | -4.733 M | -1.421 M | 237,434 | 963,777 | 1.498 M |
| Depreciation and Amortization | -910,291 | -999,939 | -510,230 | -318,088 | -106,392 |
| Depreciation | -773,697 | -895,849 | -420,115 | -299,333 | -86,265 |
| Amortisation | -136,594 | -104,090 | -90,115 | -18,755 | -20,127 |
| EBIT | -5.644 M | -2.421 M | -272,796 | 645,689 | 1.392 M |
| Pre Tax Profit | -5.847 M | -2.676 M | -195,514 | 705,139 | 1.421 M |
| Tax Expense | -199,527 | -487,497 | -153,864 | -2.23 M | -529,975 |
| Net Profit After Tax | -6.047 M | -3.163 M | -349,378 | -1.525 M | 891,368 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Preference Dividend | 0 | 0 | 0 | 0 | 0 |
| Net Abnormal Items | 2,969 | 250,952 | 313,922 | 0 | 0 |
| Reported Net Profit After Abnormal Items | -6.044 M | -2.912 M | -35,456 | -1.525 M | 891,368 |
| Ending Shares | 80.274 M | 78.238 M | 68.699 M | 68.254 M | 60.263 M |
| Weighted Average Shares | 76.591 M | 68.121 M | 67.974 M | 67.891 M | 59.636 M |
| EPS After Abnormal Items (cents) | -7.89 | -4.28 | -0.05 | -2.25 | 1.49 |
| Breakdown | 30/12/2020 | 30/12/2019 | 30/12/2018 | 30/12/2017 | 30/12/2016 |
|---|---|---|---|---|---|
| Total Current Assets | 15.979 M | 19.611 M | 15.454 M | 16.829 M | 11.061 M |
| Total Non Current Assets | 12.296 M | 12.918 M | 8.082 M | 6.548 M | 5.354 M |
| Total Assets | 28.275 M | 32.528 M | 23.537 M | 23.377 M | 16.415 M |
| Total Current Liabilities | 5.684 M | 3.48 M | 5.219 M | 5.211 M | 3.896 M |
| Total Non Current Liabilities | 5.475 M | 5.844 M | 1.302 M | 916,384 | 57,365 |
| Total Liabilities | 11.159 M | 9.324 M | 6.521 M | 6.128 M | 3.953 M |
| Net Assets | 17.116 M | 23.204 M | 17.016 M | 17.249 M | 12.462 M |
| Breakdown | 30/12/2020 | 30/12/2019 | 30/12/2018 | 30/12/2017 | 30/12/2016 |
|---|---|---|---|---|---|
| Net Operating Cash | -8.935 M | -489,340 | -1.107 M | -281,684 | 654,794 |
| Net Invested Cash | -874,191 | -820,491 | -1.403 M | -1.537 M | -2.221 M |
| Net Financing Cash Flows | -985,961 | 8.091 M | -352,453 | 5.828 M | -753,994 |
| End Cash Position | 1.874 M | 12.66 M | 5.855 M | 8.69 M | 4.591 M |
| Beginning Cash | 12.66 M | 5.855 M | 8.69 M | 4.591 M | 6.445 M |
| Exchange Rate Adjustments | 8,982 | 23,942 | 28,184 | 88,696 | 465,973 |
| Other Cash Adjustments | 0 | 0 | 0 | 0 | 0 |
| Ending Cash | 1.874 M | 12.66 M | 5.855 M | 8.69 M | 4.591 M |
© 2021 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice or ‘regulated financial advice’ under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ) at www.morningstar.com.au/s/fsg.pdf and www.morningstar.com.au/s/fapds.pdf. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Some material is copyright and published under license from ASX Operations Pty Ltd ACN 004 523 782.